Anti-Human CD20 Reference Antibody (NAV006, RUO) (HY257386)

Name: Anti-Human CD20 Reference Antibody (NAV006, RUO)
Brand: abinScience
SKU: HY257386
Price: 370 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HY257386
種反応性	Human
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG
クローンID	NAV006
生物学的活性	NAV006 (0.78-100 nM) specifically binds to CD20-positive Ramos cells in a dose-dependent manner (K d =30.5 nM) [1]. NAV006 is able to mediate a\r\nmore robust Fc receptor‑dependent cytotoxic activity (ADCC)\r\nagainst Daudi target cells in the presence of the immunosuppressive\r\nCA125 compared with parent Rituximab () [1]. NAV006 (1 mg/kg; i.p.) mediates antitumor activity in NCG mice with human lymphoma Raji cells (with a tumor growth inhibition of 95%) [2].
ターゲット	B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P11836
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	NAV006
背景	B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). 1. Li, H. et al. (2003) The Journal of biological chemistry 278, 42427-34. PMID: 12920111 2. Tedder, TF. et al. (1985) Journal of immunology (Baltimore, Md. : 1950) 135, 973-9. PMID: 3925015 3. Bubien, JK. et al. (1993) The Journal of cell biology 121, 1121-32. PMID: 7684739 4. Polyak, MJ. et al. (2008) The Journal of biological chemistry 283, 18545-52. PMID: 18474602
参考文献	1. Grasso L, et al. Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression. Oncol Lett. 2022;23(1):2. [HY257386] 2. Grasso L, et al. Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo. Antib Ther. 2025;8(3):171-176. Published 2025 Apr 24. [HY257386]
注意事項	For research use only. Not suitable for clinical or therapeutic use.